Last edition
News about "Shreeram Aradhye"
Novartis Reports Promising Results for New Anti-Malaria Drug to Tackle Growing Resistance
Novartis’ Phase III trial of KLU156 (GanLum) met its primary endpoint, showing a 97.4 percent PCR-corrected cure rate comparable to Coartem. If approved, GanLum would mark the first major malaria treatment breakthrough in over two decades, targeting drug-resistant parasites.
Shreeram Aradhye | 13/11/2025 | By Dineshwori
Novartis to Acquire Tourmaline Bio for USD 48 per share
Novartis to acquire Tourmaline Bio in a USD 1.4 billion deal, gaining rights to pacibekitug—an anti-IL-6 antibody with potential in cardiovascular disease; transaction expected to close in Q4 2025.
Shreeram Aradhye | 09/09/2025 | By Dineshwori | 161
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy